CN Patent

CN109384716B — 一种氘代喹啉化合物及其制备和用途

Assigned to Haichuang Pharmaceutical Co Ltd · Expires 2021-06-29 · 5y expired

What this patent protects

本发明提供了一种氘代喹啉化合物及其制备和用途。具体地，本发明公开了一种式(Ⅰ)所示喹啉衍生物或其立体化学异构体、溶剂合物或药学上可接受的盐。实验结果证明，本发明提供的氘代喹啉化合物具有更好的代谢稳定性和药代动力学，能够用于制备更安全有效的治疗结核病的药物，应用前景优良。

USPTO Abstract

本发明提供了一种氘代喹啉化合物及其制备和用途。具体地，本发明公开了一种式(Ⅰ)所示喹啉衍生物或其立体化学异构体、溶剂合物或药学上可接受的盐。实验结果证明，本发明提供的氘代喹啉化合物具有更好的代谢稳定性和药代动力学，能够用于制备更安全有效的治疗结核病的药物，应用前景优良。

Drugs covered by this patent

bedaquiline-fumarate (BEDAQUILINE FUMARATE)

Patent Metadata

Patent number: CN109384716B
Jurisdiction: CN
Classification: —
Expires: 2021-06-29
Drug substance claim: No
Drug product claim: No
Assignee: Haichuang Pharmaceutical Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.